John Libbey Eurotext

Hépato-Gastro & Oncologie Digestive

MENU

Polykystoses rénales et polykystoses hépatiques Volume 26, numéro 8, Octobre 2019

  • [1] Pei Y., Obaji J., Dupuis A. Unified criteria for ultrasonographic diagnosis of ADPKD. J Am Soc Nephrol. 2009;20:205-212.
  • [2] van Aerts R.M.M., van de Laarschot L.F.M., Banales J.M., Drenth J.P.H. Clinical management of polycystic liver disease. J Hepatol. 2018;68:827-837.
  • [3] Cornec-Le Gall E, Audrézet MP, Rousseau A, et al. The PROPKD score: A new algorithm to predict renal survival in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 2016 ; 27 : 942-51.
  • [4] Cornec-Le Gall E, Alam A, Perrone RD. Autosomal dominant polycystic kidney disease. Lancet 2019 ; 393 : 919-935.
  • [5] Porath B., Gainullin V.G., Cornec-Le Gall E. Mutations in GANAB, encoding the glucosidase iialpha subunit, causeautosomal-dominant polycystic kidney and liver disease. Am J Hum Genet. 2016;98:1193-1207.
  • [6] Cornec-Le Gall E., Olson R.J., Besse W. Monoallelic mutations to DNAJB11 cause atypical autosomal-dominant polycystic kidney isease. Am J Hum Genet. 2018;102:832-844.
  • [7] Lee-Law PY, van de Laarschot LFM, Banales JM, Drenth JPH. Genetics of polycystic liver diseases. Curr Opin Gastroenterol 2019 ; 35 : 65-72.
  • [8] Lanktree MB, Haghighi A, Guiard E, et al. Prevalence estimates of polycystic kidney and liver disease by population sequencing. J Am Soc Nephrol 2018 ; 29 : 2593-600.
  • [9] Cabezas O.R., Flanagan S.E., Stanescu H. Polycystic kidney disease with hyperinsulinemic hypoglycemia caused by a promotermutation in phosphomannomutase 2. J Am Soc Nephrol. 2017;28:2529-2539.
  • [10] Chauveau D., Faguer S., Bandin F. HNF1b : paradigme d’un gène du développement et émergence inattendue d’une nouvelle maladie génétique rénale. Nephrol Therap. 2013;9:393-397.
  • [11] Hildebrandt F., Benzing T., Katsanis N. Ciliopathies. N Engl J Med. 2011;364:1533-1543.
  • [12] Janssen MJ, Waanders E, Te Morsche RH, et al. Secondary, somatic mutations might promote cyst formation in patients with autosomal dominant polycystic liver disease. Gastroenterology 2011 ; 141 : 2056-2063.
  • [13] Schrier R.W., Abebe K.Z., Perrone R.D. Blood pressure in early autosomal dominant polycystic kidney disease. N Engl J Med. 2014;71:2255-2266.
  • [14] Bae K.T., Zhu F., Chapman A.B. Magnetic resonance imaging evaluation of hepatic cysts in early autosomal-dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2006;1:64-69.
  • [15] Irazabal M.V., Rangel L.J., Bergstralh E.J. Imaging classification of autosomal dominant polycystic kidney disease: A simple model for selecting patients for clinical trials. J Am Soc Nephrol. 2015;26:160-172.
  • [16] Gimpel C, Bergmann C, Bockenhauer D, et al. International consensus statement on the diagnosis and management of autosomal dominant polycystic kidney disease in children and young people. Nat Rev Nephrol. 2019 May 22. doi : 10.1038/s41581-019-0155-2.[Epub ahead of print].
  • [17] Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 2012 ; 367 : 2407-18.
  • [18] Torres VE1, Chapman AB, Devuyst O, et al. Tolvaptan in later-stage autosomal dominant polycystic kidney disease. N Engl J Med 2017 ; 377 : 1930-42.
  • [19] Gansevoort R.T., Arici M., Benzing T. Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: A position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice. Nephrol Dial Transplant. 2016;31:337-348.
  • [20] Soroka S., Alam A., Bevilacqua M. Assessing risk of disease progression and pharmacological management of autosomal dominant polycystic kidney disease: A Canadian expert consensus. Can J Kidney Health Dis. 2017;4:2054358117695784.
  • [21] Gevers TJG, Drenth JPH. Diagnosis and management of polycystic liver disease. Nat Rev Gastroenterol Hepatol 2013 ; 10 : 101-108.
  • [22] Gevers T.J., Inthout J., Caroli A. Young women with polycystic liver disease respond best to somatostain analogues: A pooled analysis of individual patient data. Gastroenterology. 2013;145:357-365.
  • [23] Neijenhuis M.K., Gevers T.J., Hogan M.C. Development and validation of a disease-specific questionnaire to assess patient-reported symptoms in polycystic liver disease. Hepatology. 2016;64:151-160.
  • [24] Kim H., Park H.C., Ryu H. Clinical correlates of mass effect in autosomal dominant polycystic kidney disease. PLoS One. 2015;10:e0144526.
  • [25] Chauveau D., Fakhouri F., Grünfeld J.P. Liver involvement in autosomal-dominant polycystic kidney disease : therapeutic dilemma. J Am Soc Nephrol. 2000;11:1767-1775.
  • [26] Jouret F., Lhommel R., Beguin C. Positron-emission computed tomography in cyst infection diagnosis in patients with autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2011;6:1644-1650.
  • [27] van Keimpema L., Nevens F., Vanslembrouck R. Lanreotide reduces the volume of polycystic liver : a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2009;137:1661-1668.
  • [28] Caroli A., Antiga L., Cafaro M. Reducing polycystic liver volume in ADPKD: Effects of somatostatin analogue octreotide. Clin J Am Soc Nephrol. 2010;5:783-789.
  • [29] Hogan M.C., Masyuk T.V., Page L.J. Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease. J Am Soc Nephrol. 2010;21:1052-1061.
  • [30] van Aerts RMM, Kievit W, D’Agnolo HMA, et al. Lanreotide Reduces Liver Growth In Patients With Autosomal Dominant Polycystic Liver and Kidney Disease. Gastroenterology 2019 ; 157 : 481-491.
  • [31] Aussilhou. B Treatment of polycystic liver disease. Update on the management. J Visc Surg. 2018;155:471-481.